BioMarin Reports Third Quarter 2026 Financial and Operating Results
PR Newswire•02/11/2026•16:03 ET
0
Key Highlights
- ➤Q3 revenue $1.025B, up 32% year over year, exceeding $1B for first time
- ➤2026 revenue guidance lowered to $3.8B-$3.9B from $3.875B-$3.925B
- ➤2026 non-GAAP diluted EPS guidance cut to $2.80-$3.10 from $4.90-$5.10
- ➤Metabolic Conditions revenue rose 44% to $744M, driven by GALAFOLD and POMBILITI + OPFOLDA
- ➤VOXZOGO HCH application receives FDA PDUFA date of May 30, 2027
Expert Statements
Alexander Hardy, President and Chief Executive Officer of BioMarin
“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin.”
Alexander Hardy, President and Chief Executive Officer of BioMarin
“We are building on this achievement by continuing to expand our pipeline through focused business development. We are excited to add our newest asset, an investigational treatment for Fabry disease, which has the potential to become the first subcutaneous enzyme therapy for this condition. With this fourth new asset added to our pipeline in 2026, we are following through on our commitment to build sustainable growth for the future.”
Alexander Hardy, President and Chief Executive Officer of BioMarin
“As we approach 2027, we are well positioned for our next chapter of growth, including the potential launch of VOXZOGO in hypochondroplasia and the continued execution of our financial and innovation strategy.”
BioMarin Reports Third Quarter 2026 Financial and Operating Results PR Newswire
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y
Get started
Create a free account to read the full story.